Brugada Syndrome Market is expected to support the growth of the American Brugada syndrome market to grow at a CAGR of ~6.60%

Pune, India, MRFR Press Release/- Market Research Future published a half-cooked research report on the Global Brugada Syndrome Market.

Market Highlights

The Brugada Syndrome Market is expected to reach USD 1.39 Billion by 2030 at 6.60% CAGR during the forecast period 2022 -2030.

Factors such as the increasing prevalence of heart diseases and rising therapeutics demand are estimated to drive the market growth during the forecast period. Additionally, advancements in diagnostic technologies boost the market. However, low awareness and lack of healthcare services in the middle and low-income countries are estimated to restrain the market growth during the projected period.

Segmentation

The global Brugada syndrome market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, the market is segmented into electrocardiogram, Electrophysiology (EP) test, genetic testing, and others. On the basis of treatment, the market is segmented into implantable cardioverter-defibrillator and drug therapy. Drug therapy is further segmented into antiarrhythmic drugs, psychotropic drugs, anesthetics/analgesics, and others. Antiarrhythmic drugs are further sub-segmented into ajmaline, allapinin, ethacizin, flecainide, pilsicainide, procainamide, propafenone, and others. Psychotropic drugs are further sub-segmented into amitriptyline, clomipramine, desipramine, lithium, loxapine, nortriptyline, trifluoperazine, and others. Anesthetics/analgesics are further segmented into bupivacaine, procaine, propofol, and others. On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, diagnostic centers, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Brugada Syndrome Market Research Report

Regional Analysis

The Americas dominates the global Brugada syndrome market owing to the increasing prevalence of heart diseases and presence of a well-developed healthcare sector within the region. Moreover, the increasing healthcare expenditure and presence of key players within the regional boundaries provide a favorable background for market growth.

Europe is the second largest in the global Brugada syndrome market. Factors such as the increasing availability of funds for research and a huge patient population followed by a well-developed healthcare sector drive the market within the region.

Asia Pacific is estimated to be the fastest growing market for Brugada syndrome. This can be attributed to the presence of developing economies such as India and China and a huge patient population. Moreover, the increasing healthcare expenditure and a rapidly developing healthcare sector boost the market growth within the region.

On the other hand, the Middle East and Africa has the least share in the global Brugada syndrome market due to the low per capita healthcare expenditure and stringent government policies, especially within the African region. It is estimated that the Middle East holds a majority of the market within the Middle Eastern and African region. 

Key Players

Some of the key players in this market are GeneDx (U.S), PGxHealth LLC (U.S), Abbott (U.S), GE Healthcare (U.K), Medtronic (U.S.), Pfizer, Inc (U.S), Boston Scientific Corporation (U.S.), GlaxoSmithKline (U.K), Eli Lilly Company (U.S), Taj Pharmaceuticals Ltd (India), and others.